Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mindset Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mindset Pharma's position in the market.
Mindset Pharma Inc. (OTCQB: MSSTF) has advanced its psychedelic medicine research through its COPE program with InterVivo Solutions. This initiative established standard pharmacokinetic data and protocols for LSD, psilocybin, and 5-MeO-DMT. CEO James Lanthier highlighted the potential market opportunity in providing benchmarking data against first-generation compounds. The program aims to create a comprehensive psychedelics benchmark reference data set, aiding the development of next-generation drugs for neurological and psychiatric disorders.
Mindset Pharma Inc. (OTCQB: MSSTF) announced that its CEO, James Lanthier, will participate in the KCSA Psychedelics Investor Conference on October 13-14, 2021. Mr. Lanthier will present live on October 14 at 10:00 a.m. ET. Mindset Pharma focuses on developing next-generation psychedelic medicines for neurological and psychiatric disorders. The conference aims to facilitate direct interaction between publicly-traded companies and investors, enhancing engagement in an innovative format.
Mindset Pharma (OTCQB: MSSTF) announced positive preclinical results for its compounds MSP-4019 and MSP-4020, demonstrating efficacy and an improved safety profile compared to 5-MeO-DMT. Utilizing conjugate amplification technology, these next-generation psychedelic medicines aim to address mental health disorders effectively. The compounds showed no signs of 5-HT syndrome, a concern with earlier drugs. The company plans to advance these candidates into clinical trials following further validation.
Mindset Pharma (OTCQB: MSSTF) has been included in the AdvisorShares Psychedelics ETF (PSIL), which focuses on investments in the burgeoning psychedelic drugs sector. This actively managed ETF primarily invests in companies that generate significant revenue from psychedelic drugs. CEO James Lanthier expressed enthusiasm over this inclusion, viewing it as a positive advancement for both the company and the broader industry. The announcement signifies growing recognition of Mindset as a leader in the psychedelic medicine market, particularly for neurological and psychiatric disorders.
Mindset Pharma Inc. (OTCQB: MSSTF) announced preclinical proof-of-concept data showcasing its candidate MSP-4018, demonstrating superior efficacy and safety compared to 5-MeO-DMT. The company is optimistic about advancing to human clinical trials due to this promising data. Observations indicated that MSP-4018 maintained locomotor activity and rearing behavior across various doses, contrasting the declines noted in 5-MeO-DMT. Mindset's proprietary Family 4 compounds highlight a commitment to developing optimized psychedelic medicines for neurological and psychiatric disorders.
Mindset Pharma has reported promising results for its lead candidate, MSP-1014, in a drug discrimination assay, demonstrating effects comparable to psilocybin. The study identified an effective dosage of 0.6 mg/kg with no adverse effects at doses up to 2 mg/kg. This further confirms MSP-1014 as a viable second-generation psychedelic drug. The company aims to continue preclinical studies and prepare for human clinical trials. The results underscore Mindset's commitment to developing next-generation psychedelic medicines for neurological and psychiatric disorders.
Mindset Pharma (OTCQB: MSSTF) has identified Treatment-Resistant Depression (TRD) and End of Life Angst as target indications for its lead candidate, MSP-1014. This drug aims to provide a safer second-generation treatment over psilocybin, which has shown efficacy in addressing these conditions. According to CEO James Lanthier, TRD affects one-third of major depressive disorder patients, representing a significant unmet need. Preclinical data shows MSP-1014 may offer improved safety and scalability compared to psilocybin, aiding in efficient manufacturing.
Mindset Pharma (OTCQB:MSSTF) announced groundbreaking advances in confirming the psychedelic effects of its novel compounds. Collaborating with InterVivo Solutions, the company has trained rats to distinguish psilocybin from saline, enhancing efficacy and safety assessments for its psychedelic drug candidates. This research noted that LSD demonstrated greater potency compared to psilocybin. CEO James Lanthier emphasized this innovative approach strengthens the potential of Mindset's compounds as they progress to clinical trials.
Mindset Pharma Inc. (OTCQB: MSSTF) announced CEO James Lanthier's participation in three upcoming virtual investor conferences. The conferences are the H.C. Wainwright 23rd Annual Global Investment Conference (Sept 13-15), Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Sept 20-23), and Maxim's Advances in Mental Health Conference (Sept 22). These events aim to showcase the company’s significant advancements in developing next-generation psychedelic therapies targeting neurological and psychiatric disorders. For more information, visit mindsetpharma.com.
Mindset Pharma Inc. (OTCQB: MSSTF) recently announced promising results from its next-generation 5-MeO-DMT drug candidates, showing a significant decrease in serotonergic toxicity. These findings reaffirm the candidates' superior efficacy and safety compared to traditional 5-MeO-DMT. According to CEO James Lanthier, the results highlight the potential for these drug candidates to provide a safer solution for clinic-based therapeutic use, potentially mitigating the health risks associated with serotonergic toxicity.